United Kingdom (UK)
Recombinant monoclonal antibody to VEGFR2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody B1C4A7.
UniProt Accession Number of Target Protein: P35968
Alternative Name(s) of Target: flk-1;FLK-1; KDR; Fetal liver kinase 1; Kinase insert domain receptor; Protein-tyrosine kinase receptor; EC:2.7.10.1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor
Immunogen: The original antibody was isolated by panning a phage display library against VEGFR2.
Specificity: The antibody is specific for VEGFR2.
Application Notes: The antibody, together with dsD7A8, was used for constructing the bispecific antibody (A7-A8)-LALA. The original and the bispecific antibody could strongly bind to the recombinant human VEGFR2 and mouse VEGFR2 (EC50 =0.107 nM and 0.466 nM for B1C4A7 and 0.128 nM and 0.598 nM for A7-A8 respectively). The bispecific antibody could strongly block ligand VEGF binding to its receptor VEGFR2 (IC50 for hVEGF-hVEGFR2 interaction was 1.29 nM for the bispecific antibody and 1.72 nM for B1C4A7 and IC50 for mVEGF-mVEGFR2 interaction was 0.801 nM for the bispecific antibody and 0.973 nM for B1C4A7). The original and bispecific antibodies could bind to KDR/PAE cell expressed human VEGFR2, mouse VEGFR2 (EC50 =0.522 nM and 0.533 nM, respectively). The bispecific antibody associated to VEGFR2 fast and dissociated slowly (KD = 47 pM for the bispecific and 752 pM for the original antibody). The bispecific antibody could bind to VEGFR2 and PDL1 simultaneously, as determined by cross binding ELISA. The bispecific antibody could block phosphorylation of human VEGFR2 and downstream molecule MAPK. The effect of the original and bispecific antibodies was examined on CT26 murine colon carcinoma cells in in vivo experiments. The results indicate that B1C4A7, D7A8, and BsAb (A7-A8) reduced volumes of the tumor. The combination of the two antibodies (B1C4A7 and D7A8) and BsAb (A7-A8) were more potent than two individual antibodies alone in reducing tumor volume in this CT26 model. The effect of the original and bispecific antibodies was examined on MC38 murine colon carcinoma cells. B1C4A7 only showed a mediate potency. In contrast, anti-PDLl antibody D7A8, BsAb (A7-A8), and combination of B1C4A7 and D7A8 completely inhibited the tumor growth (EP3411068A4).
Antibody first published in: PMID: